Breast cancer is the uncontrollable growth of tumour cells in the breasts. Generally, the cancer forms in either the lobules or the ducts of the breast. There are two types of breast cancers, invasive breast cancer and non-invasive breast cancer. During recent years, there has been an increase in the cases of breast cancer in women. Recently, breast cancer is also being detected in men. The American Cancer Society estimated that in 2015, more than 2,000 men would be diagnosed, and more than 400 men would die from the disease.

Increasing prevalence of breast cancer along with advanced technology for its diagnosis is expected to fuel the growth of the breast cancer diagnosis market during the forecast period. Moreover, the introduction of new and better products by manufacturers is anticipated to offer growth opportunities to the companies in the market.

The "Global Breast Cancer Diagnosis Market Analysis to 2028" is a specialized and in-depth study of the healthcare IT industry with a focus on the global market trend. The report aims to provide an overview of global market with detailed market segmentation by screening type, technology and geography. The global market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading breast cancer diagnosis market players and offers key trends and opportunities in the market.

The global breast cancer diagnosis market is segmented on the basis of screening type and technology. Based on screening type, the market is segmented as, laboratory tests, biopsy, imaging, and other screening types. On the basis of technology, the breast cancer diagnosis market is classified as, fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies.

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global breast cancer diagnosis market based on screening type and technology. It also provides market size and forecast till 2028 for overall market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The breast cancer diagnosis market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.

North America is expected to contribute to the largest share in the breast cancer diagnosis market in the coming years, owing to rising prevalence of breast cancer cases in the region during the recent years. Asia Pacific is expected to witness significant growth in the market during the forecast period, due to rising investment of foreign players in developing economies such as, China and India.

The report analyzes factors affecting breast cancer diagnosis market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the breast cancer diagnosis market in these regions.

The report also includes the profiles of key breast cancer diagnosis companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years. Some of the key players operating in the breast cancer diagnosis market include, Abbott, F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corporation, GENERAL ELECTRIC COMPANY, Hologic, Inc., Koninklijke Philips N.V., Micrima Limited, Provista Diagnostics, Inc., Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc. among others.